ONWARD Medical N.V.(ONWRF, ONWDB.XD,ONWD.BR), a Dutch neurotechnology company, on Tuesday reported wider net loss in its first half, compared to last year, mainly hurt by expenses. However, loss narrowed on a per share basis, amid higher revenues.
Looking forward, the company continues to expect to deliver a strong 2025 in line with expectations, with strong demand for the ARC-EX System. The firm believes that it is on track to meet its sales target for the third quarter for ARC-EX System.
For the half year, net loss of the firm widened to 21.18 million euros from a loss of 18.25 million euros a year ago. However, on a per share basis, loss narrowed to 0.47 euro from a loss of 0.53 euro last year.
Loss before taxes for the period amounted to 21 million euros, wider than loss of 18.57 million euros a year ago.
Total revenues & other income increased to 1.19 million euros from 0.21 million euros a year ago.
On Tuesday, in the Frankfurt market, the shares were trading 3.80% lower at 4.92 euros.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.